Mitsubishi Tanabe completes $357 mln purchase of Medicago

Osaka, Japan-based Mitsubishi Tanabe Pharma Corp has completed its previously-announced acquisition of  vaccines and therapeutic proteins developer Medicago Inc (TSX: MDG) for $357 million. The Québec City-based company’s shares will be de-listed from trading on the Toronto Stock Exchange this week. Medicago has since the 1990’s been backed by Canadian venture capital firms, including the Fonds de solidarité des travailleurs du Québec FTQ and Innovatech, and went public in 2006.


Mitsubishi Tanabe Pharma Completes Acquisiton of Medicago

OSAKA, Japan and QUEBEC CITY, Canada, Sept. 18, 2013 /CNW/ – Mitsubishi Tanabe Pharma Corporation (TSE: 4508) (“Mitsubishi Tanabe Pharma” or “MTPC”) and Medicago Inc. (TSX: MDG) announced today the completion of the previously announced acquisition of Medicago Inc. by MTPC.

On September 18, 2013, 9284-9686 Québec Inc.,a subsidiary of MTPC, acquired all of the outstanding common shares of Medicago, other than the common shares currently held by MTPC and Philip Morris Investments B.V. (“PMI”) an affiliate of Philip Morris International Inc., pursuant to the terms of an arrangement agreement made as of July 12, 2013. As a result, Medicago has become jointly owned by MTPC (60%) and PMI (40%). Shareholders of Medicago, as of the effective date of the arrangement, will be entitled to receive $1.16 per common share in cash, and holders of warrants and stock options will be entitled to receive a cash payment equal to the difference between $1.16 and the exercise price of any warrant or stock option they hold.

The common shares of Medicago will be delisted from trading on the Toronto Stock Exchange, at the end of trading on September 19, 2013.

“We are very pleased with the completion of this transaction and welcome Medicago to our group. We look forward to working with Medicago’s management and employees as well as all the stakeholders to develop highly effective and competitive vaccines based on Medicago’s proprietary technologies to contribute to the healthier lives of people around the world,” said Dr. Michihiro Tsuchiya, President and Chief Executive Officer of MTPC.

“I would like to sincerely thank our employees, investors , partners and board members for their important contribution leading to Medicago’s success, said Andy Sheldon, President and Chief Executive Officer of Medicago. I would also like to thank our corporate partners MTPC and PMI for their confidence in Medicago. We look forward to working closely with them to ensure our innovative, effective and cost efficient technology and products are brought to market”.

The acquisition of Medicago will be entirely satisfied with cash and sufficient funds have been deposited with Computershare Investor Services Inc. to enable it to make payments to Medicago shareholders, warrantholders and optionholders pursuant to the terms of the arrangement agreement. Letters of Transmittal have been mailed to registered shareholders of Medicago and are also available on SEDAR at The Letters of Transmittal explain how registered Medicago shareholders can deposit and obtain payment for their shares. Registered Medicago shareholders must return duly completed Letters of Transmittal to Computershare Investor Services Inc. in order to receive the consideration to which they are entitled for their shares. Non-registered shareholders should carefully follow the instructions from the broker or other financial intermediary that holds shares on their behalf.

About Medicago
Medicago is a clinical-stage biopharmaceutical company developing novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. Medicago is committed to providing highly effective and competitive vaccines and therapeutic proteins based on its proprietary VLP and manufacturing technologies. Medicago is a worldwide leader in the development of VLP vaccines using a transient expression system which produces recombinant vaccine antigens in plants. This technology has potential to offer more potent vaccines with speed and cost advantages over competitive technologies, enabling the development of a vaccine for testing in approximately one month after the identification and reception of genetic sequences from a pandemic strain. This production time frame has the potential to allow vaccination of the population before the first wave of a pandemic, and supply large volumes of vaccine antigens to the world market. Medicago also intends to expand development into other areas such as biosimilars and biodefense products where the benefits of our technologies can make a significant difference. Additional information about Medicago is available at

About Mitsubishi Tanabe Pharma
Mitsubishi Tanabe Pharma is a research-driven pharmaceutical company based in Japan, specializing in research, development and marketing of globally competitive pharmaceutical products focused on the field of autoimmune disease, diabetes and kidney disease, and CNS disease. Mitsubishi Tanabe Pharma contributes to the healthier lives of people around the world through the creation of pharmaceuticals that respond to unmet medical needs. Additional information about MTPC is available at

Forward Looking Statements
This news release includes certain forward-looking statements or forward-looking information for the purposes of applicable securities laws and such statements and information are based upon current expectations, which involve risks and uncertainties associated with Medicago’s business and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, and similar expressions to the extent they relate to Medicago or its management. The forward-looking statements are not historical facts, but reflect Medicago’s current expectations regarding future results or events. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations, including the matters discussed under “Risk Factors and Uncertainties” in Medicago’s Annual Information Form filed on March 28, 2013, with the regulatory authorities. Medicago assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.

SOURCE Medicago Inc.

For further information:
Medicago Inc.
Andy Sheldon
President and CEO
(418) 658-9393

Medicago Inc.
Christina Cameron
Investor Relations
(418) 658-9393 ext.156

For inquiries regarding Mitsubishi Tanabe Pharma Corporation:

Mitsubishi Tanabe Pharma Corporation
Yoshihisa Sasou
General Manager
Corporate Communications Department

Photo courtesy of Shutterstock.